Back to results
US 6,617,360 B1Granted
Medical treatment
AssigneeKnoll, Inc.
InventorsClifford James Bailey, Robert Brian Jones, Helen Christine Jackson
Life of this patent
Estimating the term…
Abstract
A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for reducing Insulin resistance in humans in whom Impaired Glucose Tolerance and Non-Insulin Dependent Diabetes Mellitus have not presented.
Claims14
A pharmaceutical product for improvement of weight and diabetic control in NIDDM patients, which product comprises effective amounts of a compound of formula I
- wherein R1 and R2 are independently H or methyl, or an enantiomer or pharmaceutically acceptable salt thereof, as a first active component, and an oral insulin secretagogue or insulin sensitizing agent as a second active component, in conjunction with at least one pharmaceutically acceptable diluent or carrier.
Dependencies are inferred from the claim text.